This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish

Superstring Capital sold 345,869 shares of Terns Pharmaceuticals in Q4 2025 (estimated $7.99M based on quarter-average pricing), reducing its holding to 443,777 shares valued at $17.93M; the fund's quarter-end position value fell by roughly $12.0M. Terns shares traded at $45.56 (up ~1,300% YoY) with a $4.9B market cap; the company holds ~ $1B cash runway into 2031 after a $747.5M December offering and remains clinical-stage with multiple catalysts expected this year.

Analysis

The market structure around this name now amplifies micro-flows: because ownership remains concentrated and sentiment has moved to a high-conviction, event-driven state, modest selling or delta-hedge unwind can translate into outsized intraday moves. Dealers and options market-makers will need to dynamically hedge gamma exposure around near-dated strikes, which creates pronounced two-way volatility around any new flows or headline.

Fundamentally, the security trades like a long-dated binary option on clinical execution rather than a cash-flow multiple; with near-term financing risk reduced, the next meaningful value inflection is clinical/regulatory progress. That shifts risk horizons — days/weeks for flow- and headline-driven moves, months for trial readouts and dose-selection clarity, and multi-year for commercialization outcomes — and makes skew and implied vol key signals rather than headline EPS.

Second-order winners include sophisticated flow managers and volatiltiy sellers who can harvest premium in quiet windows and quickly de-risk into run-ups; losers are buy-and-hold passive products that will lag during sharp drawdowns. Also, peer developers with adjacent programs will see correlation jumps on readouts as capital rotates; a negative outcome could cascade funding stress into smaller peers that rely on sentiment-driven crossover capital.

Contrarian opportunity: the market often overprices downside skew after a rapid repricing, offering structured ways to own upside while limiting capital at risk. Conversely, complacency around upcoming binary catalysts creates asymmetric downside if execution slips — disciplined sizing and explicit volatility risk management should define any position.

Key Decisions for Investors

• Long-dated call exposure funded with near-term call sales (TERN): Buy 9–18 month LEAP calls to capture upside from late-stage trial catalysts, sell 1–3 month calls to reduce premium outlay. R/R: limited cash outlay vs high upside; risk is short-term squeeze/assignment on sold calls—size at single-digit percent of biotech sleeve.
• Put-spread protection (TERN): Buy a 3–6 month put spread (long lower strike, short further OTM) to hedge a stock position across immediate catalyst windows. R/R: defined cost with capped downside insurance; effective when implied vol is elevated but not prohibitively expensive.
• Pair trade to isolate binary risk: Long broad biotech ETF (or diversified mid-cap biotech basket) / Short TERN equity outright for 3–6 months to neutralize sector beta and capture reversion if company-specific binary disappoints. R/R: reduces sector risk; potential loss if TERN outperforms materially on positive readouts.
• Event-driven volatility play: Buy near-dated straddles ahead of clinically material announcements only with strict size limits and predetermined exit rules (e.g., 30–50% realized P/L or 48-hour post-announcement unwind). R/R: profits from large moves regardless of direction; premium decay and adverse small moves are the main risks.